4 results on '"Blasco, Melania"'
Search Results
2. Superior Mesenteric Artery Syndrome: Clinical, Endoscopic, and Radiological Findings
- Author
-
Sinagra, Emanuele, primary, Raimondo, Dario, additional, Albano, Domenico, additional, Guarnotta, Valentina, additional, Blasco, Melania, additional, Testai, Sergio, additional, Marasà, Marta, additional, Mastrella, Vincenzo, additional, Alaimo, Valerio, additional, Bova, Valentina, additional, Albano, Giovanni, additional, Sorrentino, Dario, additional, Tomasello, Giovanni, additional, Cappello, Francesco, additional, Leone, Angelo, additional, Rossi, Francesca, additional, Galia, Massimo, additional, Lagalla, Roberto, additional, Midiri, Federico, additional, Morreale, Gaetano Cristian, additional, Amvrosiadis, Georgios, additional, Martorana, Guido, additional, Spampinato, Marcello Giuseppe, additional, Virgilio, Vittorio, additional, and Midiri, Massimo, additional
- Published
- 2018
- Full Text
- View/download PDF
3. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
- Author
-
Torrejón, Blanca, Cristóbal, Ion, Caramés, Cristina, Chamizo, Cristina, Santos, Andrea, Serna-Blasco, Roberto, García-Foncillas, Jesús, Prieto-Potín, Iván, Sanz-Alvarez, Marta, Luque, Melania, Madoz-Gúrpide, Juan, and Rojo, Federico
- Subjects
GENETICS of colon cancer ,TUMOR suppressor proteins ,PHOSPHOPROTEIN phosphatases ,GENE expression ,GENETIC mutation - Abstract
Background: The functional loss of the tumor suppressor protein phosphatase 2A (PP2A) occurs in a wide variety of human cancers including colorectal cancer (CRC), and SET overexpression has been reported as a key contributing mechanism to inhibit PP2A. Although SET binding protein 1 (SETBP1) overexpression and gain of function mutations have been described in several hematological malignancies as common events that increase the expression levels of the PP2A inhibitor SET, thereby leading to PP2A inactivation, the potential existence of SETBP1 alterations in CRC still remains unexplored.Methods: We studied the expression profile of SETBP1 by Western blot in a set of CRC cell lines and patient samples. Moreover, we performed co-immunoprecipitation assays to analyze the formation of the previously reported SETBP1-SET-PP2A inhibitory complex. Furthermore, we evaluated the mutational status of SETBP1 by pyrosequencing assays in a cohort of 55 CRC patients with metastatic disease after the immunohistochemical characterization of SET and p-PP2A expression in this cohort.Results: We found high SETBP1 expression in several CRC lines but only in two of the patients analyzed. In addition, we demonstrated the formation of the SETBP1-SET-PP2A heterotrimeric complex in CRC cells. However, we failed to detect SETBP1 mutations in any of the CRC patient samples included in the study.Conclusions: Our results suggest that SETBP1 expression is mainly similar o lower in colorectal cancer tissue compared to normal colonic mucosa. However, its overexpression is a low prevalent alteration which could contribute to inhibit PP2A in CRC through the formation of a SETBP1-SET-PP2A complex in some CRC patients. Moreover, SETBP1 mutations are, if exist, rare events in CRC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Superior Mesenteric Artery Syndrome: Clinical, Endoscopic, and Radiological Findings
- Author
-
Sergio Testai, Valentina Guarnotta, Vittorio Virgilio, Dario Raimondo, Melania Blasco, Massimo Midiri, Gaetano Cristian Morreale, Emanuele Sinagra, Massimo Galia, Valerio Alaimo, Federico Midiri, Vincenzo Mastrella, Angelo Leone, Marcello Giuseppe Spampinato, Roberto Lagalla, Francesco Cappello, Georgios Amvrosiadis, Guido Martorana, Marta Marasa, Dario Sorrentino, Domenico Albano, Francesca Rossi, Giovanni Albano, Giovanni Tomasello, Valentina Bova, Sinagra, Emanuele, Raimondo, Dario, Albano, Domenico, Guarnotta, Valentina, Blasco, Melania, Testai, Sergio, Marasà, Marta, Mastrella, Vincenzo, Alaimo, Valerio, Bova, Valentina, Albano, Giovanni, Sorrentino, Dario, Tomasello, Giovanni, Cappello, Francesco, Leone, Angelo, Rossi, Francesca, Galia, Massimo, Lagalla, Roberto, Midiri, Federico, Morreale, Gaetano Cristian, Amvrosiadis, Georgio, Martorana, Guido, Spampinato, Marcello Giuseppe, Virgilio, Vittorio, and Midiri, Massimo
- Subjects
medicine.medical_specialty ,Article Subject ,03 medical and health sciences ,0302 clinical medicine ,Weight loss ,Internal medicine ,medicine.artery ,medicine ,Superior mesenteric artery ,lcsh:RC799-869 ,Prospective cohort study ,Settore MED/12 - Gastroenterologia ,Hepatology ,business.industry ,Gastroenterology ,medicine.disease ,SMA ,Settore MED/18 - Chirurgia Generale ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,lcsh:Diseases of the digestive system. Gastroenterology ,Radiology ,superior mesenteryc artery syndrome, endoscopic finding, radiological aspects ,Presentation (obstetrics) ,medicine.symptom ,business ,Body mass index ,Superior mesenteric artery syndrome - Abstract
Background. The superior mesenteric artery (SMA) syndrome is a rare entity presenting with upper gastrointestinal tract obstruction and weight loss. Studies to determine the optimal methods of diagnosis and treatment are required. Aims and Methods. This study aims at analyzing the clinical presentation, diagnosis, and management of SMA syndrome. Ten cases of SMA syndrome out of 2074 esophagogastroduodenoscopies were suspected. A contrast-enhanced computed tomography (CECT) scan was performed to confirm the diagnosis. After, a gastroenterologist and a nutritionist personalized the therapy. Furthermore, we compared the demographical, clinical, endoscopic, and radiological parameters of these cases with a control group consisting of 10 cases out of 2380 EGDS of initially suspected (but not radiologically confirmed) SMA over a follow-up 2-year period (2015-2016). Results. The prevalence of SMA syndrome was 0.005%. Median age and body mass index were 23.5 years and 21.5 kg/m2, respectively. Symptoms developed between 6 and 24 months. Median aortomesenteric angle and aorta-SMA distance were 22 and 6 mm, respectively. All patients improved on conservative treatment. In our series, a marked (>5 kg) weight loss (p=0.006) and a long-standing presentation (more than six months in 80% of patients) (p=0.002) are significantly related to a diagnosis of confirmed SMA syndrome at CECT after an endoscopic suspicion. A “resembling postprandial distress syndrome dyspepsia” presentation may be helpful to the endoscopist in suspecting a latent SMA syndrome (p=0.02). The narrowing of both the aortomesenteric angle (p=0.001) and the aortomesenteric distance (p<0.001) was significantly associated with the diagnosis of SMA after an endoscopic suspicion; however, the narrowing of the aortomesenteric distance seemed to be more accurate, rather than the narrowing of the aortomesenteric angle. Conclusion. SMA syndrome represents a diagnostic and therapeutic challenge. Our results show the following findings: the importance of the endoscopic suspicion of SMA syndrome; the preponderance of a long-standing and chronic onset; a female preponderance; the importance of the nutritional counseling for the treatment; no need of surgical intervention; and better diagnostic accuracy of the narrowing of the aorta-SMA distance. Larger prospective studies are needed to clarify the best diagnosis and management of the SMA syndrome.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.